Switzerland: Nieba takes over from Mouritsen as CEO at Engimmune

Lars Nieba, CEO Engimmune

Engimmune Therapeutics, a biotech company developing novel T-cell receptor (TCR)-based therapeutics, has appointed Lars Nieba to the CEO position, replacing co-founder Søren Mouritsen, who is stepping down in a planned transition. Nieba brings more than 25 years of R&D, business and clinical development, venture capital, manufacturing and product strategy in biopharmaceuticals. He previously held positions…

You must be a HMI Subscriber to view this content.

Subscribe Now »